FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease

Purpose Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. Impaired lung function is associated with heightened risk for death, cardiovascular events, and COPD exacerbations. However, it is unclear if forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) differ in predictive value. Patients and Methods Data from 16,485 participants in the Study to Understand Mortality and Morbidity (SUMMIT) in COPD were analyzed. Patients were grouped into quintiles for each lung function parameter (FEV1 %predicted, FVC %predicted, FEV1/FVC). The four highest quintiles (Q2–Q5) were compared to the lowest (Q1) to assess their relationship with all-cause mortality, cardiovascular events, and moderate-to-severe and severe exacerbations. Cox-regression was used, adjusted for age, sex, ethnicity, body-mass index, smoking status, previous exacerbations, cardiovascular disease, treatment, and modified Medical Research Council dyspnea score. Results Compared to Q1 (<53.5% FEV1 predicted), increasing FEV1 quintiles (Q2 53.5–457.5% predicted, Q3 57.5–461.6% predicted, Q4 61.6–465.8% predicted, and Q5 ≥65.8%) were all associated with significantly decreased all-cause mortality (20% (4–34%), 28% (13–40%), 23% (7–36%), and 30% (15–42%) risk reduction, respectively). In contrast, a significant risk reduction (21% (4–35%)) was seen only between Q1 and Q5 quintiles of FVC. Neither FEV1 nor FVC was associated with cardiovascular risk. Increased FEV1 and FEV1/FVC quintiles were also associated with the reduction of moderate-to-severe and severe exacerbations while, surprisingly, the highest FVC quintile was related to the heightened exacerbation risk (28% (8–52%) risk increase). Conclusion Our results suggest that FEV1 is a stronger predictor for all-cause mortality than FVC in moderate COPD patients with heightened cardiovascular risk and that subjects with moderate COPD have very different risks.

[1]  V. Kim,et al.  Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial , 2019, BMJ Open Respiratory Research.

[2]  S. Yusuf,et al.  Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. , 2019, The Lancet. Global health.

[3]  Renata Ferrari,et al.  Predictors of mortality in patients with COPD after 9 years , 2018, International journal of chronic obstructive pulmonary disease.

[4]  K. Rabe,et al.  Cardiovascular disease and COPD: dangerous liaisons? , 2018, European Respiratory Review.

[5]  F. Martinez,et al.  Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events: A Cohort Analysis , 2018 .

[6]  A. Anzueto,et al.  Determinants of exacerbation risk in patients with COPD in the TIOSPIR study , 2017, International journal of chronic obstructive pulmonary disease.

[7]  A. Briggs,et al.  Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources , 2017, International journal of chronic obstructive pulmonary disease.

[8]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[9]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.

[10]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[11]  Alice M Turner,et al.  Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. , 2015, The Lancet. Respiratory medicine.

[12]  Alvar Agusti,et al.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. , 2015, Chest.

[13]  Edwin K. Silverman,et al.  Chronic obstructive pulmonary disease , 2012, Nature Reviews Disease Primers.

[14]  N. Metzdorf,et al.  Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial , 2014, BMC Pulmonary Medicine.

[15]  L. Edwards,et al.  Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality , 2014, Thorax.

[16]  D. Mannino,et al.  Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis , 2013, Thorax.

[17]  Bruce G. Link,et al.  The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. , 2013, American journal of public health.

[18]  F. Martinez,et al.  The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.

[19]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[20]  P. Burney,et al.  Forced vital capacity, airway obstruction and survival in a general population sample from the USA , 2010, Thorax.

[21]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[22]  R. Hubbard,et al.  Increased risk of myocardial infarction and stroke following exacerbation of COPD. , 2010, Chest.

[23]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[24]  D. Sin,et al.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.

[25]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[26]  Don D. Sin,et al.  Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .

[27]  M. Segal,et al.  Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. , 1995, American journal of epidemiology.

[28]  E. Metter,et al.  Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. , 1995, American journal of respiratory and critical care medicine.

[29]  D. Dockery,et al.  Chronic obstructive pulmonary disease mortality in six U.S. cities. , 1989, The American review of respiratory disease.

[30]  A. Siegelaub,et al.  Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.